Saturated Fat Versus Monounsaturated Fat and Insulin Action
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
High intakes of saturated fat are associated with diabetes. Our work has shown that the two most common fatty acids in the North American diet, palmitic acid (saturated fat) and oleic acid (monounsaturated fat) are metabolized differently and have opposite effects on fat burning. The proposed study will examine biochemical and molecular mechanisms for how a high saturated fat diet versus a low saturated fat/high monounsaturated fat diet alters the action of the hormone, insulin, in skeletal muscle.
Condition | Intervention |
---|---|
Obesity |
Dietary Supplement: High palmitate or high oleate diet |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
Official Title: | Palmitate Metabolism and Insulin Resistance |
- Whether increased palmitate balance (as measured by intake and the rate of [1-13C]-PA oxidation) causes increased insulin resistance and increased inflammatory signaling by peripheral blood mononuclear cells [ Time Frame: up to 4 yr ] [ Designated as safety issue: No ]Insulin sensitivity, inflammatory signaling, palmitate balance, and incomplete oxidation of palmitate in lean and obese young adults.
- We will examine the link between palmitate intake and balance and oxidative stress measured using muscle and peripheral blood markers of oxidative stress and antioxidant responses. [ Time Frame: up to 4 yr ] [ Designated as safety issue: No ]activation of c-Jun N-terminal kinase (JNK) and heme oxygenase 1 in skeletal muscle in response to the diets.
Estimated Enrollment: | 32 |
Study Start Date: | April 2010 |
Estimated Study Completion Date: | December 2014 |
Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: High palmitate diet
This is a solid food diet in which vegetable oils (primarily palm oil) are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts.
|
Dietary Supplement: High palmitate or high oleate diet
High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
|
Experimental: high oleate diet
This is a solid food diet in which hazelnut oil is used to create a dietary fat composition similar to the Mediterranean diet in which palmitic intake is very low and oleic acid intake is very high.
|
Dietary Supplement: High palmitate or high oleate diet
High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
|
Detailed Description:
Palmitic acid (PA), impairs insulin sensitivity in skeletal muscle, and replacing PA in the diet with oleic acid (OA), a monounsaturated fatty acid (FA), may be beneficial. The first objective of this project is to understand the effects on lipid metabolism and skeletal muscle lipid composition, insulin signaling, and inflammatory signaling of two common variations in FA composition of the diet: (1) The typical intake of North America where PA and OA are present in equal proportions (HI PA diet). (2) The Mediterranean FA composition in which PA is much lower and OA much higher (HI OA diet). PA may induce insulin resistance in skeletal muscle cells via its accumulation in lipids within muscle cells and via activation of inflammatory signaling. The second objective of this project is to assess the hypothesis that a high intake of PA will down-regulate its own one-carbon (initial) oxidation, leading to increased inflammatory signaling and decreased insulin signaling. However, there is literature evidence that FA may induce defects in insulin signaling, if FA are not completely oxidized; therefore, the third objective is to assess the hypotheses that a high PA diet may decrease complete oxidation of FA and possibly accelerate initial FA oxidation. A double-masked, cross-over trial of the effects of a high PA diet versus a high OA/low PA diet in 16 overweight or obese subjects and 16 lean subjects (aged 18 - 40 yr) will be conducted to investigate the following Specific Aims:
- To test the hypothesis that increased intake of PA will cause a decreased rate of [1-13C]-PA oxidation and will be associated with: (a) increased inflammatory signaling, within the muscle and by peripheral blood mononuclear cells; (b) Decreased insulin signaling as characterized by decreased, whole body, peripheral insulin sensitivity (euglycemic/hyperinsulinemic clamp) and, in skeletal muscle, decreased phospho-AKT (Ser473), increased phospho-IRS-1 (Ser636/Ser639), decreased tyrosine phosphorylation of IRS-1, and decreased membrane content of GLUT4.
- To test the hypothesis that increased intake of PA will cause less complete mitochondrial fatty acid oxidation, perhaps associated with dysfunction of the TCA cycle and increased reactive oxygen species formation. This hypothesis will be tested by measuring whole body and muscle (upper limb) relative rates of oxidation of [13-13C]-PA and [1-13C]-PA and by determining the serum profile of acylcarnitines, the urine concentrations of organic acids, and muscle concentrations of protein carbonyls.
- To test the hypothesis that a high PA diet will lead to less complete oxidation of FA, less insulin signaling in skeletal muscle in response to a test meal, less whole body insulin sensitivity, increased dysfunction of the TCA cycle, and greater reactive oxygen species formation compared to the results obtained in obese versus lean humans.
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy young adults,
- 18 - 40 years of age
Exclusion Criteria:
- regular aerobic exercise training,
- dyslipidemia, and
- type 2 diabetes or insulin resistance
Contact: David Ebenstein, B.A, M.S. | 802-656-9093 | David.Ebenstein@uvm.edu |
Contact: Karen I. Crain, B.A. | 802-656-9093 | Karen.Crain@uvm.edu |
United States, Vermont | |
The Unversity of Vermont Clinical Research Center at Fletcher Allen Health Care | Recruiting |
Burlington, Vermont, United States, 05401 | |
Contact: David Ebenstein, B.A., M.S. 802-656-9093 David.Ebenstein@uvm.edu | |
Contact: Karen I. Crain, B.A. (802) 656-9093 Karen.Crain@uvm.edu | |
Principal Investigator: Craig L. Kien, M.D., Ph.D. |
Principal Investigator: | Craig L. Kien, M.D, Ph.D. | The University of Vermont |
Additional Information:
Publications:
Responsible Party: | Craig Lawrence Kien, The Mary Kay Davignon Green and Gold Professor, Depts. of Pediatrics and Medicine, University of Vermont |
ClinicalTrials.gov Identifier: | NCT01612234 History of Changes |
Other Study ID Numbers: | R01DK082803 |
Study First Received: | May 29, 2012 |
Last Updated: | June 4, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Vermont:
humans lean obese saturated fat |
monounsaturated fat insulin sensitivity inflammation oxidant stress |
Additional relevant MeSH terms:
Insulin Resistance Obesity Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Overnutrition Nutrition Disorders |
Overweight Body Weight Signs and Symptoms Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on October 17, 2012